| Corbus Pharmaceuticals Holdings is a clinical stage pharmaceutical company focused on the development and commercialization of therapeutics to treat chronic and serious inflammatory and fibrotic diseases. Co.'s product, lenabasum, is a synthetic, oral, cannabinoid (CB2 agonist) designed to resolve chronic inflammation and halt fibrotic processes. Co. is developing lenabasum to treat systemic sclerosis, dermatomyositis, cystic fibrosis and systemic lupus erythematosus. Co.'s pipeline also includes CRB-4001, a peripherally-restricted, CB1 inverse agonist designed to treat organ specific fibrotic liver diseases, such as nonalcoholic steatohepatitis. The CRBP YTD return is shown above.
The YTD Return on the CRBP YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether CRBP YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the CRBP YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.